



KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

Date: 23rd May, 2025

To,

BSE Limited

Listing Department,

Phiroz Jeejeebhoy Tower,

25th Floor, Dalal Street,

Mumbai-400 001

Scrip Code – 531960

Subject: Outcome of Board Meeting held on 23rd May, 2025.

Ref: Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015

Dear Sir/Madam,

Pursuant to Regulation 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III, the Board of Directors at their meeting held on today i.e. on **Friday, 23rd May, 2025**, which commenced at **03:00 P.M.** and concluded at **04: 00 P.M.**, inter-alia has considered and approved:

1. Audited Financial Results along with Auditor's Report thereon for the quarter and financial year ended on 31st March, 2025, as prepared in accordance with Regulation 33 of the Listing Regulations and Schedule III of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules, 2015 (IND-AS). A copy of the Audited Financial Results of the Company for the quarter and financial year ended on 31st March, 2025, along with the Audit Reports and the declaration of unmodified opinion pursuant to the provisions of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed herewith as **Annexure-A**.
2. Appointment of Mr. Kalpesh Bipin Sheth (DIN: 00405151) as Managing Director of the Company w.e.f. 23rd May, 2025 for the period of five consecutive years, subject to approval of members of the Company at their ensuing General Meeting;
3. Appointment of Mrs. Heena Kalpesh Sheth (DIN: 07627681) as a Whole-time Director of the Company w.e.f. 23rd May, 2025 for the period of five consecutive years, subject to approval of members of the Company at their ensuing General Meeting;
4. Appointment of Mr. Samir Ambavi (DIN: 06888550) as an Additional Director in the category of Non-executive Director of the Company w.e.f 23rd May, 2025 to hold office upto the date of ensuing General Meeting.
5. Cessation of Mr. Amit Agrawal (DIN-00169061) from the post of Managing Director of the Company effective from the close of the business hours on 24th May, 2025 due to pre-occupation.
6. Cessation of Mr. Raghav Agrawal (DIN-02264149) from the post of Director of the Company effective from the close of the business hours on 24th May, 2025 due to pre-occupation.



KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, **Email:** investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

7. Cessation of Mr. Raghav Agrawal (DIN-02264149) from the post of Chief Financial Officer of the Company effective from the close of the business hours on 24th May, 2025 due to pre-occupation.
8. Cessation of Mr. Ayushman Khemka (DIN-07939582) from the post of director of the Company effective from the close of the business hours on 24th May, 2025 due to pre-occupation.

The details as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, with respect to change in Directors and KMP are enclosed herewith as **Annexure B**. A copy of Resignation Letters of Directors and Key Managerial Person resigning are enclosed herewith as **Annexure C**.

The financial Results are also made available on the website of the Company at www.kashyaptele-medicines.com.

You are requested to take the above information on your record.

Thanking you.

Yours faithfully,

For KASHYAP TELE-MEDICINES LIMITED

RAGHAV AGRAWAL
DIRECTOR & CFO
DIN: 02264149

Encl.: As above

**INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL FINANCIAL RESULTS AND
REVIEW OF QUARTERLY FINANCIAL RESULTS**

To,
The Board of Directors
Kashyap Tele-Medicines Limited

Opinion and Conclusion

We have (a) audited the Financial Results for the year ended March 31, 2025 and (b) reviewed the Financial Results for the quarter ended March 31, 2025 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Financial Results for the Quarter and Year Ended March 31, 2025" of **Kashyap Tele-Medicines Limited** ("the Company"), ("the Statement") being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

(a) Opinion on Annual Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Financial Results for the year ended March 31, 2025:

- i. is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Financial Results for the quarter ended March 31, 2025

With respect to the Financial Results for the quarter ended March 31, 2025, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below nothing has come to our attention that causes us to believe that the Financial Results for the quarter ended March 31, 2025, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Financial Results for the year ended March 31, 2025

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under Section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ("the ICAI") together with the ethical requirements that are



relevant to our audit of the Financial Results for the year ended March 31, 2025 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's Responsibilities for the Statement

This Statement which includes the Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Financial Results for the year ended March 31, 2025 has been compiled from the related audited financial statements. This responsibility includes the preparation and presentation of the Financial Results for the quarter and year ended March 31, 2025 that give a true and fair view of the net profit/(loss) and other comprehensive income/ (loss) and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Financial Results for the year ended March 31, 2025

Our objectives are to obtain reasonable assurance about whether the Financial Results for the year ended March 31, 2025 as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Annual Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the Listing Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Financial Results, including the disclosures, and whether the Annual Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the Annual Financial Results of the Company to express an opinion on the Annual Financial Results.

Materiality is the magnitude of misstatements in the Annual Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Financial Results for the quarter ended March 31, 2025

We conducted our review of the Financial Results for the quarter ended March 31, 2025 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the



ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

The Statement includes the results for the Quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.



For, **Ravi Karia & Associates**
Firm Registration No. 157029W
Chartered Accountants



Ravi Karia
Partner
Membership No. 161201
UDIN: 25161201BMONAX7982

Place: Ahmedabad
Date: May 23, 2025

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002
Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com
Website: www.kashyaptele-medicines.com


STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2025
(As per Regulation 33 of SEBI (LODR) Regulations, 2015 & Schedule III Companies Act, 2013 read with IND-AS)

S.No.	Particulars	INR in Lakhs Except EPS				
		Quarter Ended			Year Ended	
		31-03-2025 (Refer Note 4)	31-12-2024 (Unaudited)	31-03-2024 (Refer Note 4)	31-03-2025 (Audited)	31-03-2024 (Audited)
I	Revenue from operations	3.90	3.90	3.90	19.20	19.20
II	Other Income	-	-	0.01	0.00	0.01
III	Total Revenue (I + II)	3.90	3.90	3.91	19.20	19.21
IV	Expenses					
	(a) Cost of materials consumed	-	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	(d) Employee benefits expense	2.25	2.25	3.92	10.81	12.14
	(e) Finance Cost	-	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-	-
	(g) Other expenses	2.23	1.87	3.26	8.40	10.03
	Total expenses	4.48	4.12	7.18	19.21	22.17
V	Profit/(Loss) Before Tax (III- IV)	(0.58)	(0.22)	(3.27)	(0.01)	(2.96)
VI	Tax Expense :-					
	(a) Current tax	-	-	(0.08)	-	-
	(b) Tax relating to previous year	0.02	-	0.04	0.02	0.04
	Total Tax Expense	0.02	-	(0.04)	0.02	0.04
VII	Profit / (Loss) for the period (V - IV)	(0.60)	(0.22)	(3.23)	(0.03)	(3.00)
VIII	Other Comprehensive Income					
	A. Items that will be/will not be reclassified to profit and loss	-	-	-	-	-
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	-	-	-	-	-
	Total comprehensive income for the period (VII+VIII)	(0.60)	(0.22)	(3.23)	(0.03)	(3.00)
IX	Paid-up Equity Share Capital (Face Value of Rs. 1/- each)	477.22	477.22	477.22	477.22	477.22
X	Other Equity excluding revaluation reserves				(413.27)	(413.24)
XXII	Earnings per equity share:					
	Basic and diluted	(0.001)	(0.000)	(0.007)	(0.000)	(0.006)

*Notes Enclosed
Place : Ahmedabad
Date : 23-05-2025



For and on behalf of Board of Directors of
Kashyap Tele - Medicines Limited



Amit Agrawal
Managing Director
DIN: 00169061

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002
Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006
Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com
Website: www.kashyaptele-medicines.com

STATEMENT OF ASSETS AND LIABILITIES AS AT 31ST MARCH, 2025 (As per Regulation 33 of SEBI (LODR) Regulations, 2015 & Schedule III Companies Act, 2013 read with IND-AS)


Particulars	INR in Lakhs	
	As at 31/03/2025 (Audited)	As at 31/03/2024 (Audited)
ASSETS		
I Non-Current Assets		
(a) Property, Plant and Equipment	-	-
(b) Capital work in progress	-	-
(c) Financial Assets	-	-
(i) Investments	-	-
(ii) Other Financial Assets	0.34	0.34
(d) Other Non-Current Assets	65.43	58.43
	65.77	58.77
II Current Assets		
(a) Inventories	-	-
(b) Financial Assets	-	-
(i) Trade Receivables	-	0.60
(ii) Cash and Cash Equivalents	0.37	8.97
(iii) Investments	-	-
(iv) Loans	-	-
(c) Current Tax Assets (Net)	0.16	0.15
(d) Other current assets	-	-
	0.53	9.72
TOTAL ASSETS	66.30	68.49
EQUITY AND LIABILITIES		
I Equity		
(a) Share Capital	477.22	477.22
(b) Other Equity	(413.27)	(413.24)
	63.95	63.98
II Non Current Liabilities		
(a) Financial liabilities		
(i) Long term borrowings	-	-
(b) Deferred tax liabilities (net)	-	-
(c) Other long term liabilities	-	-
III Current Liabilities		
(a) Financial liabilities		
(i) Short term borrowings	-	-
(ii) Trade Payables	-	-
Total Outstanding dues of micro enterprises and small enterprises	-	-
Total Outstanding dues of others	-	-
(iii) Other Financial liabilities	2.35	4.50
(b) Other Current Liabilities	-	0.01
(c) Short-Term Provisions	-	-
(d) Income tax liabilities	-	-
	2.35	4.51
TOTAL EQUITY AND LIABILITIES	66.30	68.49

*Notes Enclosed

Place : Ahmedabad
Date : 23-05-2025



For and on behalf of Board of Directors of
For, Kashyap Tele - Medicines Limited



Amit Agrawal
Managing Director
DIN: 00169061

Notes to Audited Financial Results and Statement of Assets & Liabilities for the quarter and Financial year ended 31st March 2025:

1	The above Audited Financial Results and Statement of Assets & Liabilities of the Company for the quarter and financial year ended 31 st March, 2025 have been reviewed & recommended by the Audit Committee and approved by the Board of Directors in the Meeting held on 23rd May 2025.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices & policies to the extent applicable.
3	The Company is engaged in single segment i.e. 'Software Sales', therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.
4	The figures for the quarter ended 31st March, 2025 and 31st March, 2024 are the balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures upto the third quarter ended 31st December, 2024 and 31st December, 2023 respectively which were subjected to limited review.
5	Pursuant to compliance of SEBI notification No. SEBI/LAD-NRO/GN/2018/1 dated 9 th May, 2018 , a Statement Of Cash Flows for the Financial Year ended 31 st March, 2025 has also been submitted by way of a note as enclosed herewith as Annexure-A to the said notes to Audited Financial Results & Statement of Assets & Liabilities.
6	Pursuant to SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144 dated 26 th November, 2018-"Fund Raising by Issuance of Debt Securities by Large Entities"; the Company do not fall under the category of Large Corporates as per the given applicability framework of the said circular as on 31 st March, 2025.
7	A Copy of the aforesaid financial results is also available on the website of BSE Limited (www.bseindia.com) and on the website of the Company (www.kashyaptele-medicines.com).
8	Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Date : 23-05-2025
Place : Ahmedabad



**For and on behalf of Board of Directors of
For Kashyap Tele - Medicines Limited**



Amit Agrawal
Managing Director
DIN: 00169061

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com

Website: www.kashyaptele-medicines.com

Cash Flow Statement for the year ended 31ST March 2025**(As per Schedule III Companies Act, 2013 and IND-AS)**

		INR in Lakhs	
Particulars		For the Year ended 31/03/2025	For the Year ended 31/03/2024
A	Cash flow from operating activities:		
	Profit/(Loss) before tax	(0.01)	(2.96)
	Operating profit before working capital changes	(0.01)	(2.96)
	Adjustments for changes in working capital :		
	Change in trade receivables	0.60	(0.59)
	Change in other receivables	(7.00)	-
	Change in Current Liabilities & other payables	(2.17)	3.20
	Cash flow from/ (used in) operations	(8.58)	(0.35)
	Income taxes paid	0.02	(0.01)
	Net cash flow from/(used in) operating activities	(8.60)	(0.34)
B	Cash flow from investing activities:		
	Interest received	-	-
	Net cash (used in)/flow from investing activities	-	-
C	Cash flow from financing activities:		
	Interest paid		
	Net cash (used in)/flow from financing activities:	-	-
D	Net increase in cash and cash equivalents	(8.60)	(0.34)
	Cash and cash equivalents at the beginning of the year	8.97	9.31
	Cash and cash equivalents at the end of the year	0.37	8.97

Place : Ahmedabad

Date : 23-05-2025

For and on behalf of Board of Directors of
For, Kashyap Tele - Medicines Limited

Amit Agrawal
Managing Director
DIN: 00169061

KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -400002
Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad,
Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

Date: 23rd May, 2025

To,
BSE Limited
Listing Department,
Phiroz Jeejeebhoy Tower,
25th Floor, Dalal Street,
Mumbai-400 001

Scrip Code – 531960

Sub.: Submission of Declaration in respect to 'Audit Report with Unmodified Opinion' for the Audited Financial Results, Statement of Assets and Liabilities & Cash Flow Statement for the Financial Year ended on 31st March, 2025.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company do hereby confirm and declare that the Statutory Auditors of the Company M/s. Ravi Karia & Associates., Chartered Accountants, (FRN.:157029W), Ahmedabad, have expressed an Unmodified Opinion for their Independent Auditor's Report issued on Audited Financial Results, Statement of Assets and Liabilities & Cash Flow Statement for the Financial Year ended on 31st March, 2025; which are duly considered and approved by the Board of Directors on 23rd May, 2025.

You are kindly requested to acknowledge and take the above into your records.

Thanking you.

Yours faithfully,
FOR KASHYAP TELE-MEDICINES LIMITED

AMIT YAMUNADUTT AGRAWAL
MANAGING DIRECTOR
DIN: 00169061





KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

Annexure B

The brief particulars as per the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 are as below:

Sr. No.	Particulars	Mr. Kalpesh Bipin Sheth (DIN: 00405151)	Mrs. Heena Kalpesh Sheth (DIN: 07627681)	Mr. Samir Ambavi (DIN: 06888550)
1.	Reason for Change viz. Appointment and Change in designation, resignation, removal, death or otherwise	Appointment	Appointment	Appointment
2.	Date of Appointment /Change in category and Cessation (as applicable) & term of appointment	Appointment of Mr. Kalpesh Bipin Sheth (DIN: 00405151) as Managing Director of the Company w.e.f. 23 rd May, 2025 for the period of five consecutive years, subject to approval of members of the Company at their ensuing General Meeting	Appointment of Mrs. Heena Kalpesh Sheth (DIN: 07627681) as a Whole-time Director of the Company w.e.f. 23 rd May, 2025 for the period of five consecutive years, subject to approval of members of the Company at their ensuing General Meeting	Appointment of Mr. Samir Ambavi (DIN: 06888550) as an Additional Director in the category of Non-executive Director of the Company w.e.f 23 rd May, 2025 to hold office upto the date of ensuing General Meeting
3.	Brief Profile (In case of appointment)	<p>Mr. Kalpesh Bipin Sheth, son of Mr. Bipin Sheth, possesses over 30 years of professional experience, primarily in the pharmaceutical industry, with strong expertise in Sales and Marketing.</p> <p>He has contributed significantly to business strategy, revenue growth, and market expansion through:</p> <ul style="list-style-type: none">➤ Leading and implementing effective sales strategies;➤ Executing	<p>Mrs. Heena Kalpesh Sheth, daughter of Mr. Ramesh Chatrabhuj Bhuptani, has over 11 years of professional experience in administration and operational management, particularly within the pharmaceutical and allied sectors.</p> <p>She has been actively involved in:</p> <ul style="list-style-type: none">➤ Overseeing day-to-day business operations and internal coordination;➤ Managing human resources and organizational processes;➤ Supporting financial planning and administrative budgeting;➤ Driving improvements in internal systems and	<p>Mr. Samir Ambavi has over 18 years of experience in the outsourcing industry. He has extensive experience in managing financial and accounting processes for large client portfolios and leading sizable teams. His expertise includes overseeing complex projects, ensuring timely delivery, and maintaining adherence to Service Level Agreements (SLAs). Mr. Ambavi has also managed transitions of revenue accounting processes across multiple geographies and industries.</p>



KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, **Email:** investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

		<p>impactful marketing and brand-building initiatives;</p> <p>➤ Expanding market presence through strategic partnerships;</p> <p>➤ Ensuring adherence to regulatory and compliance frameworks; and</p> <p>➤ Mentoring and developing high-performing teams.</p> <p>His leadership and domain knowledge have been instrumental in enhancing organizational performance and market competitiveness.</p>	<p>operational efficiency;</p> <p>➤ Facilitating compliance and stakeholder communication.</p> <p>Her administrative acumen and leadership have supported the enhancement of organizational performance and governance standards.</p>	
4.	Disclosure of relationships between Directors (in case of appointment of a Director)	Spouse of Mrs. Heena Kalpesh Sheh	Spouse of Mr. Kalpesh Bipin Sheh	Director is not related to any other Director of the Company



KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai –400002

Corp. Off. : UL/8, Upper Floor, Suryarath Complex, Panchwati 1st Lane Ambawadi, Ahmedabad, Gujarat-380006

Phone: +91-6359637788, Email: investor.relations@kashyaptele-medicines.com,

Website: www.kashyaptele-medicines.com

Sr. No.	Particulars	Mr. Amit Agrawal (DIN-00169061)	Mr. Raghav Agrawal (DIN-02264149)	Mr. Ayushman Khemka (DIN-07939582)
1.	Reason for Change viz. Appointment and Change in designation resignation, removal, death or otherwise	Resignation	Resignation	Resignation
2.	Date of Appointment /Change in category and Cessation (as applicable)	24 th May, 2025	24 th May, 2025	24 th May, 2025
3.	Brief Profile (In case of appointment)	Not Applicable	Not Applicable	Not Applicable
4.	Disclosure of relationships between Directors (in case of appointment of a director)	Not Applicable	Not Applicable	Not Applicable
5.	Names of listed entities in which the resigning Director holds Directorships, indicating the Category of Directorship and membership of board committees, if any	Directorships in Listed Companies: Jindal Worldwide Limited – Managing Director Memberships in Board Committees: Audit Committee- Member Stakeholders Relationship Committee – Member Corporate Social Responsibility Committee - Member	Directorships in Listed Companies: NIL Memberships in Board Committees: NIL	Directorships in Listed Companies: NIL Memberships in Board Committees: NIL

AMIT YAMUNADUTT AGRAWAL

Address: Jindal-Opp Ketav Petrol Pump, Nr. Polytecnic,
Ambawadi, Ahemdabad 380015 Gujarat, India.

Date: 23rd May, 2025

To,

The Board of Directors

KASHYAP TELE-MEDICINES LIMITED

Corp. Off. : "Suryarath", 1st Floor, Panchwati,
1st Lane, Ambawadi, Ahmedabad – 380006.

Dear Sir / Madam,

Subject: Resignation from the post of Managing Director of Kashyap Tele-Medicines Limited ('the Company').


I, Amit Yamunadutt Agrawal, hereby tender my resignation from the post of Managing Director of the Company with effect from closure of business hours of 24th May, 2025, due to pre-occupations.

I hereby confirm that there are no other material reasons other than those provided above.

I would like to take this opportunity to convey my sincere thanks to, Board Members, Management Committee Members and all with whom, I have worked during my tenure with the Company.

Thanking you,

Yours' faithfully



AMIT YAMUNADUTT AGRAWAL
DIRECTOR
DIN: 00169061

RAGHAV AGRAWAL

Amitara, Panchvati 1st Lane,
B/h Bank of India, Ambawadi,
Ahmedabad 380006, Gujarat, India.

Date: 23rd May, 2025

To,
The Board of Directors
KASHYAP TELE-MEDICINES LIMITED
Corp. Off. : "Suryarath", 1st Floor, Panchwati,
1st Lane, Ambawadi, Ahmedabad – 380006.

Dear Sir / Madam,

Subject: Resignation from the post of Director of Kashyap Tele-Medicines Limited ('the Company').

I, Raghav Agrawal, hereby tender my resignation from the post of Director of the Company with effect from the closure of business hours of 24th May, 2025, due to pre-occupation.

I hereby confirm that there are no other material reasons other than those provided above.

I would like to take this opportunity to convey my sincere thanks to, Board Members, Management Committee Members and all with whom, I have worked during my tenure with the Company.

Thanking you,

Yours' faithfully



RAGHAV AGRAWAL
DIRECTOR
DIN: 02264149

RAGHAV AGRAWAL

Amitara, Panchvati 1st Lane,
B/h Bank of India, Ambawadi,
Ahmedabad 380006, Gujarat, India.

Date: 23rd May, 2025

To,
The Board of Directors
KASHYAP TELE-MEDICINES LIMITED
Corp. Off. : "Suryarath", 1st Floor, Panchwati,
1st Lane, Ambawadi, Ahmedabad – 380006.

Dear Sir / Madam,

Subject: Resignation as Chief Financial Officer (Key Managerial Personnel) of the Company.

I, Raghav Agrawal hereby tender my resignation from the position of Chief Financial Officer (Key Managerial Personnel) of Kashyap Tele-Medicines Limited ("KTML") with effect from close of business hours of 24th May, 2025 due to pre-occupation.

I take this opportunity to convey my sincere thanks to the leadership team, the Board Members and the entire team at KTML for the support and assistance extended to me during my association with KTML.

Kindly acknowledge, accept the resignation and relieve me from the position of Chief Financial Officer (Key Managerial Personnel) from close of business hours of 24th May, 2025.

Thanking you,

Yours' faithfully



RAGHAV AGRAWAL
CHIEF FINANCIAL OFFICER

AYUSHMAN KHEMKA

15, Unique Park, Satellite, Opp. ISRO, Manekbag,
Ahmedabad-380015, Gujarat, India.

Date: 23rd May, 2025

To,
The Board of Directors
KASHYAP TELE-MEDICINES LIMITED
Corp. Off. : "Suryarath", 1st Floor, Panchwati,
1st Lane, Ambawadi, Ahmedabad – 380006.

Dear Sir / Madam,

Subject: Resignation from the post of Director of Kashyap Tele-Medicines Limited ('the Company').

I, Ayushman Khemka, hereby tender my resignation from the post of Director of the Company with effect from the closure of business hours of 24th May, 2025, due to pre-occupation.

I hereby confirm that there are no other material reasons other than those provided above.

I would like to take this opportunity to convey my sincere thanks to, Board Members, Management Committee Members and all with whom, I have worked during my tenure with the Company.

Thanking you,

Yours' faithfully

*Ayushman
Khemka*

AYUSHMAN KHEMKA
DIRECTOR
DIN: 07939582